All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
During the last steering committee (SC) meeting, held on May 19, 2022, the SC members discussed the tests needed for risk stratification in ALL. The session was chaired by Jan Cools and included Oliver Ottmann, Sabina Chiaretti, Wendy Stock, Hervé Dombret, Mark Litzow, and André Baruchel.
Key topics of discussion included: “Why should genetics and MRD assessments be combined” and “Is there an optimal time point for MRD testing.”
Which tests are needed for risk stratification in ALL
How I sequence treatment for R/R B-ALL
During the last steering committee meeting (SC), held on May 19, 2022, the SC members discussed sequencing treatment in R/R B-ALL. The session was chaired by Hervé Dombret and included Wendy Stock, André...
What is the cellular origin of ALL?
During the EHA 2022 Congress, we spoke with Jan Cools, VIB-KU Leuven Center for Cancer Biology, Leuven, BE. We asked, What is the cellular origin of acute lymphoblastic leukemia (ALL)?
Subscribe to get the best content related to ALL delivered to your inbox